Class IOngoingVoluntary: Firm initiated
AKKARCO LLC: food recall H-1196-2026
AKKARCO LLC of Lorton, VA recalled Ashfiat Alharamain Energy Support 250ml/8fl. oz. Reason: Undeclared tadalafil. The FDA listed it as Class I in its Enforcement Report dated Aug 12, 2026; distribution: nationwide.
Record status as published: Ongoing. openFDA data last updated Oct 21, 2026.
Have this product? Check FDA.gov and your retailer. This page reproduces an FDA Enforcement Report record and is not a public alert. Look for the firm's recall notice on the FDA's recalls page, or ask the store where you bought it what to do. If you think you got sick from a food, contact a health care provider.
Recall details
- Product
- Ashfiat Alharamain Energy Support 250ml/8fl. oz.
- Product quantity
- 1052 units
- Reason for recall
- Undeclared tadalafil
- Codes, lots and dates on the package
- Batch No: ENGOT24 EXP: OCT 2028 UPC: 1234561870003
- Distribution pattern
- The product was distributed nationwide through third-party e-commerce marketplace: Amazon.com
- Recalling firm
- AKKARCO LLC, Lorton, VA
- Classification
- Class I — the FDA uses this class for a situation in which there is a reasonable probability that using or being exposed to the product will cause serious adverse health consequences or death.
- Voluntary or mandated
- Voluntary: Firm initiated
- How the firm first notified customers
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Advertisement
Dates
| Event | Date |
|---|---|
| Recall initiated by the firm | Jan 28, 2026 |
| Classified by the FDA | Aug 4, 2026 |
| Published in the Enforcement Report | Aug 12, 2026 |
Advertisement
OpenPlate shows FDA records as published and does not add new findings. Product names and company names belong to their owners.
Sources
- U.S. Food and Drug Administration, openFDA food enforcement reports, recall number H-1196-2026 (openFDA record). Data provided by the U.S. Food and Drug Administration (https://open.fda.gov).
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service. The FDA does not endorse OpenPlate.